目的 探讨高通量血液透析对长期血液透析患者血清β2-微球蛋白(β2-MG)浓度的影响及 临床意义。 方法 选择26例长期血液透析患者（高通量组14例，低通量组12例），高通量和低通量透析器均选用聚砜膜，表面积均为1.3m2，分别测定两组患者研究开始第一次透析治疗前、后治疗2周和6个月时透析前血清β2-MG浓度，同时观察关节痛程度的变化。 结果 高通量透析能有效清除血液透析患者体内的β2-MG，单次高通量透析后患者血清β2-MG的下降率达45.2％；高通量组患者血清β2－MG浓度在治疗开始、2周及6个月时分别为：66.3 mg/L、51.2 mg/L和47.6 mg/L，同时关节痛症状改善，而低通量组均无明显变化。 结论 高通量透析能够缓解长期血液透析患者的关节痛症状，这与高通量透析有效清除并持续降低血液透析患者血清β2-MG浓度有关，透析膜的通量是影响清除血液透析患者血清β2-MG的主要因素。

Objective To investigate the effect of high-flux hemodialysis on the serum beta 2-microglobulin(β2-MG) in long-term hemodialysis patients. Method Twenty-six long-term hemodialysis patients were selected, including 14 high-flux dialysis Group patients and 12 low-flux dialysis Group patients. The serum β2-MG levels were measured at the start and at the 2 weeks, 6 months of this study. The symptoms of joint pain were evaluated. Results The serum β2-MG levels decreased significantly after high-flux dialysis. The percent reduction of β2-MG levels was 45.2% by the first high-flux dialysis. At start and 2 weeks, 6 months of this study, The serum β2-MG levels in high-flux dialysis patients were 66.3 mg/L, 51.2 mg/L and 47.6 mg/L, respectively. The symptoms of joint pain significantly improve of in high-flux dialysis patients. During the 6 months of low-flux dialysis,the plasma β2-MG levels(66.8 mg/L and 65.5 mg/L at the beginning and at the end of low-flux dialysis) and symptoms of joint pain unchanged. Conclusion Our study demonstrated that symptoms of joint pain are improved significantly with high-flux dialysis which is an effective treatment to decrease the serum β2-MG levels in long-term hemodialysis patients. Membrane flux is the main determinant of β2-MG levels in long-term hemodialysis.